The UK at the Forefront of Innovative Drug-Radiotherapy Combination Clinical Trials: Introducing the CONCORDE Platform.
C Faivre-Finn, S Brown, A Ryan...
https://pubmed.ncbi.nlm.nih.gov/32107107/Actively Recruiting
Led by University of Leeds · Updated on 2025-12-19
200
Participants Needed
14
Research Sites
104 weeks
Total Duration
Researchers are evaluating new DNA damage repair inhibitors DDRis combined with radiotherapy for patients with stage IIB to IIIB non-small cell lung cancer NSCLC in this Phase IB study. The purpose is to find the recommended dose and safety of DDRis given with a fixed dose of curative radiotherapy, followed by up to 12 months of consolidation durvalumab immunotherapy in some groups. The study uses a specialized method to monitor dose-limiting toxicities over 13.5 months to guide safe dosing decisions. Participants receive radiotherapy administered in 30 daily fractions of 2Gy each, totaling 60Gy Monday to Friday. Some groups also receive oral DDRi drugs such as Olaparib, AZD1390, Ceralasertib, or AZD5305 alongside radiotherapy. Selected groups receive up to 12 months of durvalumab immunotherapy after radiotherapy. No placebo is used both patients and doctors know the assigned treatments. One study arm was discontinued. During the study, patients are closely followed to monitor side effects, cancer response, and treatment compliance. Blood samples are collected to track progress and explore which patients may benefit most. Researchers assess dose-limiting toxicities up to 13.5 months after radiotherapy start and evaluate safety, response, disease control, survival, and quality of life up to two years post-treatment. Participation lasts through treatment and follow-up periods for comprehensive monitoring.
CONDITIONS
A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC
J
Jamie B Oughton, MPhil
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Leeds
Lead Sponsor
University of Manchester
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Approximately 6 weeks of radiotherapy followed by up to 12 months of durvalumab immunotherapy in selected arms
Participants receive radiotherapy once daily Monday to Friday for a total of 30 sessions (fractions). Depending on the assigned study arm, participants may also receive a DNA damage response inhibitor (DDRi) drug alongside radiotherapy. Following radiotherapy, eligible participants in some arms receive up to 12 months of durvalumab immunotherapy.
Daily visits Monday to Friday for radiotherapy; additional visits for durvalumab infusions every 4 weeks during consolidation phase
Duration - Up to 2 years after completion of radiotherapy
Participants are followed closely to monitor side effects, assess cancer response, and collect blood samples to evaluate treatment progress and predict benefits.
Regular follow-up visits over 2 years post-treatment
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
7
Have more questions? Get in touch with our team for quick support
C Faivre-Finn, S Brown, A Ryan...
https://pubmed.ncbi.nlm.nih.gov/32107107/Katrina Walker, Samantha Hinsley, Rachel Phillip...
https://pubmed.ncbi.nlm.nih.gov/36446040/Gerard M Walls, Jamie B Oughton, Anthony J Chalmers...
https://pubmed.ncbi.nlm.nih.gov/33072895/University of Leeds
Lead Sponsor
University of Manchester
Collaborating Sponsor